About PureTech Health plc
https://www.puretechhealth.comPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States.
CEO
Robert Lyne
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : A+
Price Target
Institutional Ownership
LANSDOWNE PARTNERS (UK) LLP
Shares:14.11M
Value:$267.6M
PENTWATER CAPITAL MANAGEMENT LP
Shares:75K
Value:$1.42M
MILLENNIUM MANAGEMENT LLC
Shares:17.84K
Value:$338.44K
Summary
Showing Top 3 of 8
About PureTech Health plc
https://www.puretechhealth.comPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $1.85M ▼ | $24.88M ▼ | $-44.6M ▼ | -2.41K% ▼ | $-1.9 ▼ | $-46.24M ▼ |
| Q4-2024 | $4.03M ▲ | $112.65M ▲ | $95.28M ▲ | 2.37K% ▲ | $3.5 ▲ | $101.97M ▲ |
| Q2-2024 | $288K ▲ | $27.76M ▼ | $-41.77M ▼ | -14.5K% ▲ | $-1.5 ▼ | $-64.58M ▼ |
| Q4-2023 | $178.57K ▼ | $67.8M ▼ | $-40.37M ▼ | -22.61K% ▼ | $-0.74 ▼ | $-11.17M ▲ |
| Q2-2023 | $3.15M | $76.25M | $-25M | -793.81% | $-0.45 | $-36.55M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $321.55M ▼ | $553.24M ▼ | $184.22M ▼ | $375.98M ▼ |
| Q4-2024 | $367.31M ▼ | $602.63M ▲ | $194.7M ▼ | $414.71M ▲ |
| Q2-2024 | $500.42M ▲ | $579.95M ▼ | $273.74M ▲ | $315.87M ▼ |
| Q4-2023 | $327.14M ▼ | $693.97M ▲ | $235.74M ▲ | $464.07M ▼ |
| Q2-2023 | $352.14M | $693.55M | $184.66M | $513.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-44.6M ▼ | $-46.34M ▲ | $29.93M ▲ | $-3.81M ▼ | $-20.04M ▲ | $-45.94M ▲ |
| Q4-2024 | $69.56M ▲ | $-53M ▲ | $1.95M ▼ | $22.31M ▲ | $-27.83M ▼ | $-54.37M ▲ |
| Q2-2024 | $-41.77M ▲ | $-80.01M ▼ | $236.51M ▲ | $-39.1M ▼ | $117.41M ▲ | $-80.01M ▼ |
| Q4-2023 | $-65.7M ▼ | $-39.94M ▲ | $-105.44M ▼ | $-14.38M ▼ | $-159.43M ▼ | $-40.12M ▲ |
| Q2-2023 | $-25M | $-65.13M | $173.88M | $91.9M | $200.15M | $-65.2M |
CEO
Robert Lyne
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : A+
Price Target
Institutional Ownership
LANSDOWNE PARTNERS (UK) LLP
Shares:14.11M
Value:$267.6M
PENTWATER CAPITAL MANAGEMENT LP
Shares:75K
Value:$1.42M
MILLENNIUM MANAGEMENT LLC
Shares:17.84K
Value:$338.44K
Summary
Showing Top 3 of 8